Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From LivaNova PLC
The market for surgical heart valve replacement devices is projected to steadily decline, as newer, more innovative transcatheter techniques poach customers, according to a new report from Informa’s Meddevicetracker.
In a series on articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are six new anti-infectives expected to reach the market for the first time next year, all with an above average likelihood of approval.
BIO chief calls US Defense Production Act ‘misguided’ as India seeks more COVID vaccines; America will donate AstraZeneca vaccine – just as soon as the FDA determines it was adequately manufactured.
Prices for J&J and Pfizer’s COVID-19 vaccines will be watched closely as India permits private sales. While demand is set to spike with age criteria for those eligible to receive the shots expanded, local manufacturers Serum Institute and Bharat Biotech are ramping up capacities with the government’s help.
- Implantable Devices
- Other Names / Subsidiaries
- Caisson Interventional, LLC
- CardiacAssist, Inc.
- Cyberonics, Inc., Ela Medical
- ImThera Medical, Inc.
- Sorin Group, Sorin S.p.A.
- Sulzer CarboMedics, Inc.